Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709823 · ClinicalTrials.gov registry record · Phase 2
Trial of Cytisine in Adult Smokers
A Phase 2 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT03709823 is a Phase 2 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 254 participants.
The verdict
NCT03709823, a Phase 2 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily \[TID\] schedule) within a 25-day treatment period.
Interventions
- DRUG Placebo Comparator
- BEHAVIORAL Behavioral support
- DRUG Cytisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2019-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03709823
The ClinicalTrials.gov registry entry for NCT03709823 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT03709823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03709823 about?
NCT03709823 is a clinical study titled "Trial of Cytisine in Adult Smokers". This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily \[TID\] schedule) within a 25-day treatment period.
What is the current status of trial NCT03709823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2018-11-13. Estimated completion is 2019-04-23.
What interventions are being tested in trial NCT03709823?
The interventions under investigation include: Placebo Comparator (DRUG), Behavioral support (BEHAVIORAL), Cytisine (DRUG).
Who is sponsoring clinical trial NCT03709823?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.